Abstract. Infantile hepatic hemangioma (IHH) can be accompanied by consumptive hypothyroidism. We report the case of a 4-mo-old boy who showed massive hepatomegaly, peripheral coldness, lethargy, and failure to thrive. An enhanced computed tomography scans demonstrated multiple hemangiomas in both lobes of the liver, and a thyroid function tests showed severe hypothyroidism: TSH 561.5 µIU/mL, free triiodothyronine (fT 3 ) 1.0 pg/mL, and free thyroxine (fT 4 ) < 0.7 ng/dL. IHH gradually regressed following propranolol treatment and fT 4 increased to a low normal level (1.0 ng/dL) by high dose replacement of levothyroxine, while fT 3 remained very low (< 1.0 pg/mL), even following high doses of levothyroxine; fT 3 eventually normalized following the administration of liothyronine. We suggest that treatment strategies should be individualized based on thyroid function, and that the combination therapy of propranolol for anti-tumor treatment and levothyroxine and liothyronine for respective thyroid hormone replacement is effective, particularly in cases of severe consumptive hypothyroidism due to multiple IHHs.
Introduction
Infantile hepatic hemangioma (IHH) is a benign tumor, with around 5-10 cases occurring per year in Japan (1) . The pathological features of IHH have not been fully elucidated, but are likely caused by neoplastic proliferation of endocapillary cells or vascular anomalies (2) . IHH often undergoes spontaneous gradual involution; however, in some cases of IHH, intervention is mandatory because of serious complications including heart failure, respiratory distress, coagulation abnormality (KasabachMerritt syndrome), or compartment syndrome. Consumptive hypothyroidism is one such complication of IHH, occurring in 5.3% of all IHH cases (1) . Iodothyronine deiodinase is highly expressed in hepatic hemangioma cells and inactivates both triiodothyronine and thyroxine (3) . While the traditional treatment for IHH was systemic steroid or interferon administration, propranolol is the currently recommended treatment choice (4, 5) . Here, we report the case of a 4-mo-old boy with severe IHH-mediated consumptive hypothyroidism that was improved by propranolol-containing combination therapy administration, and review previous cases that were treated with propranolol.
Case Report
The patient was a 4-mo-old boy with abdominal distension, which had been present for 2 mon. He was delivered at 38 wk of gestation with no asphyxia, weighing 3432 g. His mother was diagnosed with mild hypothyroidism (TSH 7.339 µIU/mL, fT 4 1.10 ng/dL, fT 3 3.12 pg/mL) during fertility treatment and was prescribed a 3-mo course of levothyroxine; she became pregnant 8 mo later and displayed normal thyroid function throughout the pregnancy. The patient's newborn screening tests were all normal, including thyroid function (TSH 3.6 µIU/ mL, fT 4 2.71 ng/dL), although at birth he had a 2 cm diameter subcutaneous hemangioma on his forehead that was successfully treated by laser ablation. Other than the subcutaneous hemangioma, he did not show any abnormal growth, development, or physical examination findings at his routine checkup at 1 mo of age.
Abdominal distension was noticed in the patient at 2 mo of age, which progressively worsened. When medical attention was sought at 4 mo of age, his liver was palpable 5 cm below the right costal margin on the right midclavicular line; he also had several features suggestive of hypothyroidism including peripheral coldness, lethargy, and failure to thrive (Fig. 1 ). His length was 59.6 cm (< 3rd percentile, -2.1 SD), weight was 5980 g (10th percentile, -1.3 SD), and head circumference was 40.0 cm (90-97th percentile, -0.4 SD). Thyroid ultrasonography revealed the maximum transverse diameter was 28.7 mm (+ 0.2 SD), and an enhanced abdominal computed tomography scans showed multiple tumors unevenly occupying both lobes of the liver (Fig. 2 ) and replacing most of the normal hepatic architecture. The findings of peripheral rim contrast enhancement in the arterial phase led to a diagnosis of IHH. The tumor marker alpha-fetoprotein (AFP) was 23900 ng/mL (with low serum L3 isozyme, 1.9%), excluding the possibility of hepatoblastoma or hepatocellular carcinoma. Head magnetic resonance imaging and abdominal ultrasonography did not show hemangioma in any other organs. A blood test revealed severe hypothyroidism (TSH 561.5 µIU/mL, fT 3 1.0 pg/mL, and fT 4 < 0.7 ng/dL), with negligible anti-thyroid autoantibodies (anti-thyroglobulin antibody 15.6 IU/mL and anti-thyroid peroxidase antibody 9.7 IU/mL). The patient also had cardiomegaly (cardiothoracic ratio 61% on chest X-ray); however, ejection fraction did not decrease (63.2%). He did not have any other complications such as respiratory failure, coagulation disorder, or compartment syndrome. The patient was diagnosed with IHH and consumptive hypothyroidism.
Due to the size of the IHH and the severity of the hypothyroidism, we simultaneously started propranolol treatment and levothyroxine replacement. Propranolol was started at 0.25 mg/kg/d, and gradually increased to 2.0 mg/ kg/d for 3 wk in the absence of adverse events such as hypoglycemia or bradycardia (Fig. 3) ; no adverse events were observed in our patient during the period of propranolol treatment. Vol.28 / No.1 mm, and propranolol was stopped at 1 yr and 1 mo of age; serum AFP levels declined to within normal limits within a month of propranolol treatment initiation. At the latest visit at 1 yr and 5 mo of age, the patient acquired catch-up growth, and his psychomotor development was not delayed. No evidence of IHH regrowth was observable via ultrasonography.
Discussion
Our patient had the most severe described case of IHH-mediated consumptive hypothyroidism subsequently treated with propranolol ( Table 1) . As his newborn screening of thyroid function was normal, it is unlikely that he had congenital hypothyroidism. The cause of such severe hypothyroidism in our patient is unclear; however, we hypothesized that the large IHH tumor mass was likely associated with high activity of type 3 iodothyronine deiodinase, although tumor volumetry data were not available in our patient. Consistent with this assumption, and based on an evaluation of all previous cases, Luongo et al. (6) speculated that the severity of hypothyroidism is proportional to the size of the tumor and its specific activity. However, further investigation is required to fully evaluate the relationship between IHH tumor volume and deiodinase enzymatic activity. Immediate normalization of thyroid function, as well as tumor regression, is mandatory for avoiding irreversible developmental delay in these patients. Our patient was successfully treated by the combination of propranolol and thyroid hormone supplementation, avoiding such complications. As described above, levothyroxine was initially started as a monotherapy; however, subsequent addition of liothyronine was required. This was surprising as levothyroxine monotherapy was effective in the majority of previously reported cases of consumptive hypothyroidism, except for case 6 in Table  1 -this patient required co-administration of liothyronine and levothyroxine to normalize thyroid function. Considering the possibly high consumption rate of T 3 and T 4 in large tumors, the combined replacement of levothyroxine and liothyronine could be more beneficial than high dose levothyroxine monotherapy; combination therapy may also be a better option for initial treatment in cases such as ours. However, when serum fT 4 is normal and fT 3 is reduced, we may use liothyronine supplementation alone, as reported by Higuchi et al. (7) . Based on these data, we suggest that treatment strategies should be individualized based on thyroid function, and that the combination of propranolol for anti-tumor treatment and levothyroxine and liothyronine for thyroid supplementation is an effective treatment option, particularly in cases of severe consumptive hypothyroidism due to multiple IHHs and probable high activity type 3 iodothyronine deiodinase activity.
Conclusion
We successfully managed severe hypothyroidism due to multiple IHHs in a pediatric patient using the combination therapy of propranolol for anti-tumor treatment and levothyroxine and liothyronine for thyroid hormone replacement. We suggest that treatment strategies should be individualized depending on thyroid function, and that this combination therapy is particularly effective in cases of severe consumptive hypothyroidism due to multiple IHHs and probable high type 3 iodothyronine deiodinase activity. 
